Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Phase 1b Trial of Irak 1/4 Inhibition for Low-Risk Myelodysplastic Syndrome Refractory/Resistant to Prior Therapies: A Trial in Progress

Guillermo Garcia-Manero, Lewis R. Silverman, Lucy Yan

Blood (2023) 142 (Supplement 1): 3247.

https://doi.org/10.1182/blood-2023-172511

Published: 2023

Journal Articles

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Daniel I. Nathan, Ronald Hoffman, Daiva Ahire, John Mascarenhas, Lewis R. Silverman, Vesna Najfeld, Jonathan Feld

Blood (2023) 142 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2023-179585

Published: 2023

Journal Articles

Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome

Shivani Handa, Namrata Sonia Chandhok, Sudhamsh Reddy Desai, Asem Berkalieva, Erin Moshier, Douglas Tremblay, Lewis R. Silverman, Trent Wang, Uroosa Ibrahim, Aditi Shastri, Jonathan Feld

Blood (2023) 142 (Supplement 1): 3239.

https://doi.org/10.1182/blood-2023-190346

Published: 2023

Journal Articles

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Blood (2023) 142 (Supplement 1): 321.

https://doi.org/10.1182/blood-2023-181795

Published: 2023

Journal Articles

Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients

Richa Rai, Camille Bigenwald, Jonathan Feld, Stella Melana, Erin P. Demakos, Amir Horowitz, Lewis R. Silverman

Blood (2022) 140 (Supplement 1): 11432–11433.

https://doi.org/10.1182/blood-2022-170922

Published: 2022

Journal Articles

Central Nervous System Specific Characteristics and Outcomes in Acute Myeloid Leukemia Patients with Neurologic Involvement

Dahniel Sastow, Yosef J.R.A Riazat-Kesh, Kyle Farina, Jonathan Feld, Michal Bar-Natan, Alla Keyzner, Lewis R. Silverman, Marina Kremyanskaya, John Mascarenhas, Douglas Tremblay

Blood (2022) 140 (Supplement 1): 11618–11620.

https://doi.org/10.1182/blood-2022-157300

Published: 2022

Journal Articles

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Metodi Balev, Nicole Zubizarreta, Erin Bresnahan, Jonathan Feld, Marina Kremyanskaya, Alla Keyzner, Alan H. Shih, Bridget K Marcellino, Lewis R. Silverman, Michal Bar-Natan, John Mascarenhas, Douglas Tremblay

Blood (2022) 140 (Supplement 1): 139–140.

https://doi.org/10.1182/blood-2022-167828

Published: 2022

Journal Articles

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

Richa Rai, Foramben Patel, Jonathan Feld, Stella Melana, Shyamala C. Navada, Rosalie Odchimar-Reissig, Erin P. Demakos, E. Premkumar Reddy, Lewis R. Silverman

Blood (2021) 138 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2021-152764

Published: 2021

Journal Articles

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Richa Rai, PhD, Foramben Patel, MS, Stella Melana, PhD, Jonathan Feld, MD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142908

Published: 2020

Journal Articles

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

Jonathan Feld, MD, Erin P. Demakos, RN, Rosalie Odchimar-Reissig, RN, Douglas Tremblay, MD, Saudia Alli, NP, Darshanie Sewah, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138969

Published: 2020

Journal Articles

T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG

Jonathan Feld, MD, Jane Houldsworth, PhD, Asha Reddy, MS, Zinnia Mai, BS, Shafinaz Hussein, MD, Shyamala C. Navada, MD, Lewis R. Silverman, MD, Meenakshi Mehrotra, PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-143083

Published: 2020

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Journal Articles

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

Camille Bigenwald, MD, Amir Horowitz, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Richa Rai, PhD, Stella Melana, PhD, Erin P. Demakos, RN, Miriam Merad, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 2986.

https://doi.org/10.1182/blood-2019-124887

Published: 2019

Journal Articles

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Jonathan Feld, MD, Francesca Schieppati, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4260.

https://doi.org/10.1182/blood-2019-128656

Published: 2019

Journal Articles

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Guillermo Garcia-Manero, MD, Shyamala C. Navada, MD, Pierre Fenaux, MD PhD, Patrick S. Zbyszewski, MBA, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4268.

https://doi.org/10.1182/blood-2019-132149

Published: 2019

Journal Articles

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4231.

https://doi.org/10.1182/blood-2019-130747

Published: 2019

Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman

Blood (2019) 134 (Supplement_1): 829.

https://doi.org/10.1182/blood-2019-122896

Published: 2019

Journal Articles

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Richa Rai, PhD, Stella Melana, PhD, Shyamala C. Navada, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, E. Premkumar Reddy, PhD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2018-99-119266

Published: 2018

Journal Articles

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

John Roboz, Shyamala C. Navada, MD, Sool Yeon Cho, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2018) 132 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2018-99-115169

Published: 2018

NARROW

Phase 1b Trial of Irak 1/4 Inhibition for Low-Risk Myelodysplastic Syndrome Refractory/Resistant to Prior Therapies: A Trial in Progress

The Presence of Ring Chromosomes in Patients with Myeloid Neoplasms Is Predictive of a Poor Outcome

Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome

Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis

Aberrant Proportion of Monocyte Subsets in Bone Marrow of High-Risk Myelodysplastic Syndrome Patients

Central Nervous System Specific Characteristics and Outcomes in Acute Myeloid Leukemia Patients with Neurologic Involvement

Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line

Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic

T-Cell Monoclonality As Assessed By TCR-Sequencing: A Potential Biomarker of Response in Patients with MDS with Autoimmune Cytopenias Treated with IVIG

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome

Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS)

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only